Indivior (NASDAQ:INDV) Rating Increased to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Indivior (NASDAQ:INDV) from a hold rating to a strong-buy rating in a research note released on Monday,Zacks.com reports.

INDV has been the topic of a number of other research reports. Weiss Ratings downgraded Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday. HC Wainwright upped their price objective on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a report on Monday, January 12th. Northland Securities set a $50.00 target price on Indivior in a research note on Tuesday, January 20th. Finally, Morgan Stanley restated an “overweight” rating and set a $36.00 target price on shares of Indivior in a report on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $39.33.

Indivior Price Performance

INDV opened at $30.53 on Monday. The firm has a 50 day simple moving average of $33.42 and a 200 day simple moving average of $30.76. Indivior has a fifty-two week low of $8.64 and a fifty-two week high of $38.00. The company has a market cap of $3.82 billion, a price-to-earnings ratio of 18.62 and a beta of 0.83.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.17. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. The firm had revenue of $358.00 million for the quarter, compared to analysts’ expectations of $305.62 million. As a group, analysts expect that Indivior will post 1.22 EPS for the current year.

Insider Buying and Selling

In other Indivior news, Director Mark Stejbach acquired 775 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director owned 16,847 shares of the company’s stock, valued at $596,215.33. This trade represents a 4.82% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stuart A. Kingsley bought 940 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an average cost of $31.86 per share, with a total value of $29,948.40. Following the completion of the purchase, the director owned 5,582 shares in the company, valued at $177,842.52. This represents a 20.25% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 5,842 shares of company stock valued at $203,342.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of INDV. Caitong International Asset Management Co. Ltd increased its position in shares of Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after acquiring an additional 460 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in Indivior by 3.4% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company’s stock valued at $761,000 after acquiring an additional 700 shares in the last quarter. Blue Trust Inc. lifted its position in Indivior by 17.8% in the 4th quarter. Blue Trust Inc. now owns 4,859 shares of the company’s stock valued at $176,000 after acquiring an additional 733 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after purchasing an additional 781 shares during the period. Finally, Salomon & Ludwin LLC acquired a new position in Indivior in the 4th quarter worth $30,000. Institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.